Chetta, Alfredo
Yorgancioglu, Arzu
Scuri, Mario
Barile, Sara
Guastalla, Daniele
Dekhuijzen, P. N. Richard
Article History
Received: 2 November 2020
Accepted: 3 February 2021
First Online: 25 February 2021
Ethics approval and consent to participate
: Both studies were approved by an independent ethics committee (Ospedale Maggiore di Parma), and were performed in accordance with the principles of the Declaration of Helsinki, and the International Conference on Harmonisation notes for guidance on Good Clinical Practice (ICH/CPMP/135/95). All patients provided written informed consent prior to any study-related procedure.
: Not applicable.
: AC has received grants from Menarini, GlaxoSmithKline and Astra Zeneca, and personal fees from Chiesi. AY has received grants from MSD, AstraZeneca and Sanofi, speakers bureau honoraria from AstraZeneca, Abdi İbrahim, GlaxoSmithKline, Novartis Sandoz, Sanofi, Chiesi, and DEVA Pharmaceutique, and funding from WHO, the Turkish Ministry of Health, GARD, GINA, and ERS. MS, SB and DG are employees of Chiesi Farmaceutici SpA, the sponsor of the two studies. PNRD has received grants and personal fees from Chiesi, AstraZeneca, GlaxoSmithKline, Glenmark, Mylan, Teva, Mundipharma, and Boehringer Ingelheim.